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Abstract Background Pharmacists’ involvement in patient
care has improved the quality of care and reduced medication
errors. However, this has required a lot of work that could not
have been accomplished without documentation of interven-
tions. Several means of documenting errors have been pro-
posed in the literature but without a consistent comprehensive
process. Recently, the American College of Clinical Phar-
macy (ACCP) recognized that pharmacy practice lacks a
consistent process for direct patient care and discussed several
options for a pharmaceutical care plan, essentially encom-
passing medication therapy assessment, development and
implementation of a pharmaceutical care plan and finally
evaluation of the outcome. Therefore, as per the recommen-
dations of ACCP, we sought to retrospectively analyze
interventions by grouping them according to medication
related problems (MRP) and their nodes such as prescribing;
administering; monitoring; documenting and dispensing.
Objective The aim of this study is to report interventions
according to medication error (ME) nodes and show the
impact of pharmacy interventions in reducing MRPs. Setting
The study was conducted at the cardiology and infectious
diseases services at a teaching hospital located in Beirut,
Lebanon. Methods Intervention documentation was com-
pleted by pharmacy students on infectious diseases and car-
diology rotations then reviewed by clinical pharmacists with
respective specialties. Before data analysis, a new pharmacy
reporting sheet was developed in order to link interventions
according to MRP. Then, MRPs were grouped in the five ME
nodes. During the documentation process, whether MRP had
reached the patient or not may have not been reported which
prevented the classification to the corresponding medication
error nodes as ME. Main outcome Reduction in medication
related problems across all ME nodes. Results A total of
n = 1174 interventions were documented. N = 1091 inter-
ventions were classified as MRPs. Interventions were ana-
lyzed per 1000 patient days and resulted in 340 medication
related problem/1000 patient days. A 72 % reduction in MRP
across all ME nodes was seen. The majority of interventions
were in the field of cardiology followed by infectious disease
related. When interventions per ME nodes were analyzed, a
high percentage of intervention acceptance was noted across
all nodes especially prescribing (68.30 %) monitoring
(77.7 %) and in documenting errors (79.36 %). Conclusion
The role of pharmacists in reducing preventable MRPs can be
shown when pharmacy interventions are analyzed according
to corresponding MRP and ME nodes.
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Impact of findings on practice
• The documentation and analysis of interventions in
mediciation related problems is useful.
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• A clinical pharmacist attending the rounds helps to
decrease the number of medication related problems
and potential medication errors.
• High rate of physician acceptance to pharmacist’s
interventions should encourage interdisciplinary col-
laboration on rounds.
Introduction
A medication error (ME) is any preventable event that may
cause or lead to inappropriate medication use or patient
harm while the medication is within the control of the
healthcare professional, patient, or consumer [1, 2]. ME
comprise any error in the medication use process, irre-
spective of whether an injury or the potential for an injury
occurred [3]. Some MEs do not cause harm while others
are caught before harm occurs (‘‘near-misses’’). MEs may
originate at any stage of the drug-use process including
prescribing, dispensing, administering, monitoring, and
documenting [4]. Medication related problems (MRP) have
been defined as negative consequences of medications that
can harm or potentially harm patients [5].
The involvement of pharmacists in the medication use
process, as members of the healthcare team, improves the
quality of patient care by preventing medication errors
(MEs) [1, 6]. According Bates [7], pharmacists are com-
petent in the monitoring of error frequencies and also near
misses. Pharmacy interventions can be defined as any
recommendation to a healthcare provider by pharmacists
that aim to change patient management or therapy [8].
Although the definition of intervention is well understood
by pharmacist vernacular, its scope of interpretation may
be ambiguous to other healthcare providers and hospital
administrators [8]. Furthermore, it was assessed that doc-
umenting and quantifying pharmacy interventions in terms
of medication error preventions might result in a greater
appreciation of pharmacists by hospital administrators and
risk management.
At the Lebanese American University School of Phar-
macy (LAU SOP) in Lebanon, pharmacy students are
involved in direct patient care during their introductory and
advanced pharmacy practice experiences (IPPE, APPE) in
compliance with the accreditation Standards of American
Colleges of Pharmacy Education (ACPE) [9]. Students on
APPE rotations round with clinical pharmacy faculty and
are required to document their interventions after having
discussed them with clinical pharmacy faculty on service.
The documentation tool/intervention sheet (Appendix 1,
Supplementary material) used at LAU SOP was adopted in
2003 based upon published literature [6]. Interventions are
aggregated and used to document pharmacy’s contribution
to patient care. It was hoped that presenting accepted
interventions in terms of prevented medication related
problems would strengthen the recognition of clinical
pharmacy services by hospital administrators.
The need to develop reporting systems able to capture
pharmacy interventions and report MEs has been previ-
ously recognized [1]. Recently, the American College of
Clinical Pharmacy (ACCP) recognized that the pharmacy
practice lacks a consistent process for direct patient care
and discussed several options for a pharmaceutical care
plan, essentially encompassing medication therapy assess-
ment, development and implementation of a pharmaceuti-
cal care plan and finally evaluation of the outcome [10].
Therefore, as per the recommendations of ACCP, inter-
ventions were retrospectively analyzed by grouping them
according to MRPs.
Aim of the study
The objective of this study is to show the impact of phar-
macy interventions in reducing MRPs when medication
error (ME) nodes are used as a mean of reporting.
Ethics approval
The study was approved by the LAU Institutional Review
Board (IRB). The results were reported in aggregate.
Neither physicians nor patients names were identified nor
linked to identifiers. Due to the retrospective nature of the
study, a consent form was not needed.
Methods
All interventions that were prospectively documented on
infectious diseases and cardiology services during the
inclusive period of September 2012 through May 2013
were retrospectively reviewed and analyzed. These two
services were the first to be launched during this period.
Prior to analyzing the data, a new pharmacy reporting sheet
was developed by the authors to link interventions
according to MRPs. The form was designed to prompt the
user to focus on assessing the medication regimen for
MRPs and then to road map a plan, via an intervention.
The new form was tailored to group pharmacy inter-
ventions within seven categories of MRPs. The MRP cat-
egories were based on the individualized medication
assessment and planning tool (iMAP) process of a phar-
maceutical care plan [5] (Appendix 2, Supplementary
material). Furthermore, MRPs were classified into one of
the five nodes of MEs based on where they originate in the
drug-use process (Table 1). Similar associations have been
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previously published, linking ME categories to reasons for
MEs [1, 4]. The authors classified overlapping MRPs such
as suboptimal drug versus suboptimal duration, frequency
or administration when related to the prescribing process
such as a physician prescribed a suboptimal duration, fre-
quency or administration, based upon text descriptions of
the interventions in the database. If no text was provided,
the aforementioned MRPs were classified as prescribing
errors. The MRP, Fear of non-adherence was not classified
into a ME node. Drug information questions were not
considered as MRPs and were therefore not classified.
Interventions were reviewed by the authors who are
specialists in Infectious diseases and cardiology and the
therapeutic class as per American Hospital Formulary
Service (AHFS) recommendations was added into the
database [11]. During the prospective reporting of inter-
ventions, students did not always document whether the
MRP had reached the patient or not. Therefore, it was not
possible to classify the corresponding medication error
nodes as ME according to the National Coordinating
Council for Medication Error Reporting and Prevention
(NCC-MERP) [12].
Data analysis
Data were entered on an excel spread sheet. Records for
entry with incomplete data were excluded. The statistical
analysis was carried out using IBM-SPSS version 22
software for Windows Release (IBM Corp. Released 2013.
IBM SPSS Statistics for Windows, Version 22.0. Armonk,
NY: IBM Corp.). Descriptive statistics, such as percent-
ages, were used to summarize the data and report the fre-
quency distribution of intervention categories, MRPs,
respective drug classes as well as other expressive results.
All results are reported utilizing the new reporting; 6
intervention major categories, 22 subcategories, 7 MRPs
and 5 ME nodes.
Results
During this one year period, a total of n = 1174 interventions
were made, which consisted of n = 83 drug information
questions. The remaining n = 1091 interventions were clas-
sified as MRPs. These interventions were documented on
n = 3217 patient days. Analyzing the interventions and
MRPs per 1000 patient days resulted in 360 intervention/1000
patient days and 340 medication related problem/1000 patient
days, respectively. Out of the n = 1174 interventions, 72 %
were accepted. This translates into approximately 72 %
prospective reduction in MRP across ME nodes related to
prescribing, monitoring and documenting (Fig. 1). The
majority of interventions were cardiology related interven-
tions 508 (43.3 %) while 453 (38.6 %) were infectious disease
related and 213 (18.1 %) were miscellaneous. When classi-
fying the medication according to AHFS drug class, the anti-
infective agents were the most intervened on drug class cap-
turing a total of 448 (38.2 %) followed by cardiovascular
drugs, and blood formation and coagulation with 245 (20.9 %)
and 204 (17.4 %) respectively.
The top five medications associated with pharmacist
interventions in terms of cardiology were atorvastatin,
aspirin, bisoprolol, enoxaparin, furosemide and clopido-
grel. In Infectious Diseases, the top five medications were
vancomycin, amoxicillin-clavulanate, meropenem, imipe-
nem and fluconazole.
Table 1 Medication related
problems grouped into
medication error nodes
Medication error node
(where the initial error
occurred)
Medication related problems
(reasons for the medication error)
Prescribing Drug therapy needed including prescription omissions
Suboptimal dosing
Suboptimal drug
Suboptimal duration, frequency or administration when related to the
prescribing process such as a physician prescribed a suboptimal
duration, frequency or administration
Administration Suboptimal duration, frequency or administration when related to the
administering process such as a nurse administered the medication
with a suboptimal duration, frequency or administration despite
having an appropriate physician prescription
Monitoring Medication monitoring needed
Documenting Documentation error including incomplete orders, medication
discrepancy due to lack of reconciliation and transcription errors
Dispensing Suboptimal drug
Drug information and medication counseling were not classified into medication error nodes
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Out of n = 1174 interventions most of the recommen-
dations were reported under the major intervention cate-
gories of pharmacotherapeutic recommendation followed
by patient care. Table 2 summarizes the findings of major
intervention categories. In terms of subcategories, the most
common pharmacist interventions were focused on dosing,
addition and discontinuation of medications. The inter-
vention subcategories pin point the overall efforts of where
pharmacist interventions took place as well as per spe-
cialty. In both specialties, the interventions were mostly
pertaining to prescribing (Table 3).
As for the MRPs, the most common were suboptimal
dosing followed by suboptimal drug and suboptimal
duration, frequency or administration (Table 4). The total
n = 1091 MRPs were considered for classification into ME
nodes. We excluded all n = 77 fear of non-adherence
MRPs, because it is not a well-established medication
related problem. This resulted in a total of n = 1014
classifiable MRPs (Table 1). The origin of the errors
showed 834 (82.2 %) of the MRPs were related to the
prescribing node, 126 (12.4 %) to the documentation node
and 54 (5.3 %) to the monitoring node. No MRPs origi-
nated from the dispensing or administration nodes. Fur-
thermore, when interventions were analyzed per ME nodes,
a high percentage of intervention acceptance was noted
across the nodes, 570 (68.30 %) in prescribing, 42
(77.77 %) in monitoring and 100 (79.36 %) in document-
ing errors (Fig. 1).
Discussion
The majority of the interventions were secondary to MRPs
originating from prescribing, documenting and monitoring
error nodes. The most common MRPs in cardiology were
suboptimal dosing and drug therapy needed which prompted
pharmacists to recommend the initiation of venous throm-
boembolism (VTE) prophylaxis, early initiation of beta
blocker and angiotensin converting enzyme (ACE) inhibi-
tors in patients post-acute coronary syndromes, optimization
of bridge therapy in VTE treatment and modification of
statin doses according to indication and patient specific
characteristics. In regards to dose adjustments, enoxaparin
was the most common drug intervened on according to renal
function and indication, followed by statins dose modifica-
tion. Sequentially, the interventions that predominately
corresponded to drug therapy needed were the addition of
ACE inhibitors/angiotensin receptor blocker for indications
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Fig. 1 Pharmacy Interventions
classified according to
medication error (ME) nodes
Table 2 Intervention (major categories)
Cardiology
N (%)
Infectious diseases
N (%)
Other
N (%)
Total
N (%)
Categories
Allergy/disease state contraindication 5 (1 %) 3 (0.7 %) 7 (3.3 %) 15 (1.3 %)
Alternate route 10 (2 %) 26 (5.7 %) 49 (23 %) 85 (7.2 %)
Drug information 47 (9.3 %) 20 (4.4 %) 16 (7.5 %) 83 (7.1 %)
Interactions/incompatibility 10 (2 %) 10 (2.2 %) 7 (3.3 %) 27 (2.3 %)
Order clarification 36 (7.1 %) 5 (1.1 %) 19 (8.9 %) 60 (5.1 %)
Patient care 84 (16.5 %) 29 (6.4 %) 23 (10.8 %) 136 (11.6 %)
Pharmacotherapeutic recommendation 316 (62.2 %) 360 (79.5 %) 92 (43.2 %) 768 (65.4 %)
Total 508 (100 %) 453 (100 %) 213 (100 %) 1174 (100 %)
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such as post-acute coronary syndrome, secondary prevention
for coronary artery disease and others. In infectious disease,
the most common MRPs were suboptimal dosing and sub-
optimal drug which led to dose adjustments and de-escala-
tion of therapy. Examples of the interventions were mostly
related to the dosing adjustments of both carbapenems and
vancomycin. As for the MRP suboptimal drug, the most
common interventions were discontinuation of both fluoro-
quinolones and carbapenems (Fig. 2).
Analyzing the data as MRPs allows the pharmacist to
highlight the potential medication errors that require corrective
actions within the institution, whereas data as interventions
allows the identification of corrective actions that were rec-
ommended by a pharmacist to implement a care plan. It is also
worth mentioning that one MRP may have necessitated the
implementation of multiple interventions within the pharma-
cist’s care plan, and this is reflected within the results of 340
MRP/1000 patient days that necessitated a total of 360 inter-
ventions/1000 patient days to be recommended.
As expected, given that the pharmacists were rounding
on the specialty services of cardiology and infectious dis-
eases, the most commonly intervened on medications were
Table 3 Interventions (subcategories)
Cardiology
N (%)
Infectious disease
N (%)
Other
N (%)
Total
N (%)
Subcategories
Adjust frequency and duration 11 (2.2 %) 52 (11.5 %) 7 (3.3 %) 70 (6 %)
Change to more effective drug 15 (3 %) 23 (5.1 %) 6 (2.8 %) 44 (3.7 %)
Change to a more effective route 0 1 (0.2 %) 1 (0.5 %) 2 (0.2 %)
Check labs 13 (2.6 %) 33 (7.3 %) 6 (2.8 %) 52 (4.4 %)
Clarified type of allergic reaction 3 (0.6 %) 3 (0.7 %) 3 (1.4 %) 9 (0.8 %)
Dose 115 (22.6 %) 143 (31.6 %) 18 (8.5 %) 276 (23.5 %)
Drug addition 109 (21.5 %) 25 (5.5 %) 18 (8.5 %) 152 (12.9 %)
Drug discontinuation 35 (6.9 %) 69 (15.2 %) 33 (15.5 %) 137 (11.7 %)
Drug information 47 (9.3 %) 20 (4.4 %) 16 (7.5 %) 83 (7.1 %)
Drug interaction 10 (2 %) 10 (2.2 %) 7 (3.3 %) 27 (2.3 %)
Enforced the documentation of allergy in the medical record 2 (0.4 %) 0 1 (0.5 %) 3 (0.3 %)
Formulary conversion 2 (0.4 %) 2 (0.4 %) 1 (0.5 %) 5 (0.4 %)
Identified a drug induced ADR 14 (2.8 %) 10 (2.2 %) 1 (0.5 %) 25 (2.1 %)
Incomplete order 36 (7.1 %) 5 (1.1 %) 19 (8.9 %) 60 (5.1 %)
IV to po 10 (2 %) 26 (5.7 %) 48 (22.5 %) 84 (7.2 %)
Medication counseling 54 (10.6 %) 19 (4.2 %) 4 (1.9 %) 77 (6.6 %)
Medication reconciliation 28 (5.5 %) 5 (1.1 %) 18 (8.5 %) 51 (4.3 %)
Other 0 0 4 4 (0.3 %)
Pharmacokinetic consult 1 (0.2 %) 0 0 1 (0.1 %)
Recommend a pharmacoeconomic alternative 0 3 (0.7 %) 0 3 (0.3 %)
Warned about a pertinent ADR 3 (0.6 %) 4 (0.9 %) 2 (0.9 %) 9 (0.8 %)
Total 508 (100 %) 453 213 1174 (100 %)
Table 4 Medication related problems (MRPs)
Cardiology Infectious disease Others Total
Drug therapy needed 109 (23.6 %) 25 (5.8 %) 18 (9.1 %) 152 (13.9 %)
Suboptimal dosing 115 (24.9 %) 143 (33 %) 18 (9.1 %) 276 (25.3 %)
Medication monitoring needed 17 (3.7 %) 37 (8.5 %) 8 (4.1 %) 62 (5.3 %)
Suboptimal drug 76 (16.5 %) 117 (27 %) 48 (24.4 %) 241 (22.1 %)
Documentation problems 69 (15 %) 13 (3 %) 44 (22.3 %) 126 (11.5 %)
Suboptimal duration, frequency, or administration 21 (4.6 %) 79 (18.2 %) 57 (28.9 %) 157 (14.4 %)
Fear of non-adherence 54 (11.7 %) 19 (4.4 %) 4 (2 %) 77 (7.1 %)
Total 461 (100 %) 433 (100 %) 197 (100 %) 1091 (100 %)
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anti-infective agents, cardiovascular drugs, and blood for-
mation and coagulation, which is in line with previous
reports showing that these drug classes were mostly asso-
ciated with MEs. For instance, the Medication Error
Detection, Amelioration and Prevention (MEDAP) Study
reported that the most common drug classes associated
with MEs were systemic anti-infective followed by
hematologic and cardiovascular drugs [4, 13–16].
The most common origins for error were prescribing,
followed by documentation errors, then monitoring errors.
This is also in line with the MEDAP study where prescribing
administering and monitoring were in the top three common
origins for error [4]. However, unlike the MEDAP study, no
errors originated at the level of dispensing or administration
which is due to the fact that the MRPs and subsequent
interventions were made during interdisciplinary rounds
with physicians, focusing on prescribing errors, rather than
being at the bedside during nursing rounds or during the
dispensing process in main pharmacy. In previous studies,
prescribing errors were reported and mostly associated with
anti-infectives in the inpatient setting and with cardiovas-
cular medications in the outpatient setting [13, 17]. Similar to
our findings other studies reported that dosing errors were
more frequent than wrong drug selection [14–21].
Classifying MRPs within seven categories segregates
problematic processes within an institution (Table 4).
Pharmacy leaders can utilize MRP and ME nodes quan-
tification to highlight issues within the medication use
process. Furthermore, presenting MRPs may be helpful to
identify targets for quality initiatives within the institution.
Strengths
This paper reflects interventions as the number of pre-
vented MRPs per medication error node. Since MRPs can
be classified into ME nodes, it becomes easier for the
pharmacist to identify performance improvement projects
and advocate for optimal patient care. It may also serve as
an educational tool train IPPEs and APPEs student phar-
macists on how to use a stepwise approach in identifying
MRPs, developing care plans and quantifying medication
error nodes to target improvement projects.
Limitations
Although the study does not report on the severity of the
interventions or the associated cost, the most common
problems led the pharmacists to intervene on medications
associated with important, well documented clinical
outcome measures related to antibiotic stewardship and
anticoagulation dosing [22]. Furthermore, the retrospec-
tive nature of the study hindered the ability to classify
ME according to NCCMERP. Despite the limitation of
not being able to quantify MEs it was still possible to
highlight the role of a pharmacist in providing patient
centered care by intervening on frequent medication error
nodes. Another limitation is that no MRPs were cate-
gorized in the dispensing or administering ME nodes
which shows bias due to the reporter. These results
further emphasize the need to promote documentation
and analysis of interventions according to this process by
students on IPPE rotations in hospital pharmacy and staff
pharmacists as well. Furthermore, it identifies that more
effort should be allocated towards interdisciplinary col-
laboration between pharmacy and nursing to recognize
and prevent medication related problems pertaining to
administration. These results further support the recom-
mendation by the institute of medicine (IOM) which calls
for interdisciplinary collaboration to prevent MEs
[2, 4, 23, 24].
Furthermore, we believe that these results in addition to
previously published literature supporting the presence of a
clinical pharmacist on rounds to decrease medication
errors, should further decrease the reluctance of hospital
administrators to recruit clinical pharmacists [25].
Conclusion
Analyzing pharmacy interventions according to corre-
sponding MRPs facilitated the recognition of pharmacy’s
role in reducing preventable MRPs across the medication
error nodes of prescribing, documenting, and monitoring.
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